Clinical consensus and progress of prophylactic cranial irradiation

Abstract

Liu Yandong, Zhou Juying. Clinical consensus and progress of prophylactic cranial irradiation[J]. Journal of International Oncology, 2017, 44(3): 217-220.

［1］ Aupérin A, Arriagada R, Pignon JP, et al. Prophylactic cranial irradiation for patients with smallcell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group［J ］. N Engl J Med, 1999, 341(7): 476-484. DOI: 10.1056/NEJM199908123410703. ［2］ Schild SE, Foster NR, Meyers JP, et al. Prophylactic cranial irradiation in smallcell lung cancer: findings from a North Central Cancer Treatment Group Pooled Analysis［J］. Ann Oncol, 2012, 23(11): 2919 -2924. DOI:10.1093/annonc/mds123. ［3］ Zhang W, Jiang W, Luan L, et al. Prophylactic cranial irradiation for patients with smallcell lung cancer: a systematic review of the literature with metaanalysis［J］. BMC Cancer, 2014, 14: 793. DOI: 10.1186/1471240714793. ［4］ Rule WG, Foster NR, Meyers JP, et al. Prophylactic cranial irradiation in elderly patients with small cell lung cancer: findings from a North Central Cancer Treatment Group pooled analysis［J］. J Geriatr Oncol, 2015, 6(2): 119-126. DOI:10.1016/j.jgo.2014.11.002. ［5］ Le Péchoux C, Dunant A, Senan S, et al. Standarddose versus higher dose prophylactic cranial irradiation (PCI) in patients with limitedstage smallcell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 9901, EORTC 2200308004, RTOG 0212, and IFCT 9901): a randomised clinical trial［J］. Lancet Oncol, 2009, 10(5): 467-474. DOI: 10.1016/S14702045(09)701019. ［6］ Wolfson AH, Bae K, Komaki R, et al. Primary analysis of a phase Ⅱrandomized trial Radiation Therapy Oncology Group (RTOG) 0212: impact of different total doses and schedules of prophylactic cranial irradiation on chronic neurotoxicity and quality of life for patients with limiteddisease smallcell lung cancer［J］. Int J Radiat Oncol Biol Phys, 2011, 81(1): 7784. DOI: 10.1016/j.ijrobp.2010.05.013. ［7］ Sun A, Bae K, Gore EM, et al. Phase Ⅲ trial of prophylactic cranial irradiation compared with observation in patients with locally advanced non smallcell lung cancer: neurocognitive and qualityoflife analysis［J ］. J Clin Oncol, 2011, 29(3): 279-286. DOI: 10.1200/JCO.2010.29.6053. ［8］ Won YW, Joo J, Yun T, et al. A nomogram to predict brain metastasis as the first relapse in curatively resected nonsmall cell lung cancer patients［J］. Lung Cancer, 2015, 88(2): 201-207. DOI: 10.1016/j.lungcan.2015.02.006. ［9］ Zhang F, Zheng W, Ying L, et al. A nomogram to predict brain metastases of resected nonsmall cell lung cancer patients［J］. Ann Surg Oncol, 2016, 23(9): 30333039. DOI: 10.1245/s1043401652063. ［10］ Lee DS, Kim SJ, Kang JH, et al. Serum carcinoembryonic antigen levels and the risk of wholebody metastatic potential in advanced nonsmall cell lung cancer［J］. J Cancer, 2014, 5(8): 663-669. DOI: 10.7150/jca.9871. ［11］ Horinouchi H, Sekine I, Sumi M, et al. Brain metastases after definitive concurrent chemoradiotherapy in patients with stage Ⅲ lung adenocarcinoma: carcinoembryonic antigen as a potential predictive factor［ J］. Cancer Sci, 2012, 103(4): 756-759. DOI: 10.1111/j.13497006201202217.x. ［12］ Hubbs JL, Boyd JA, Hollis D, et al. Factors associated with the development of brain metastases: analysis of 975 patients with early stage nonsmall cell lung cancer［J］. Cancer, 2010, 116(21): 5038-5046. DOI: 10.1002/cncr.25254. ［13］ Gore EM, Bae K, Wong SJ, et al. Phase Ⅲ comparison of prophylactic cranial irradiation versus observation in patients with locally advanced nonsmallcell lung cancer: primary analysis of radiation therapy oncology group study RTOG 0214［J］. J Clin Oncol, 2011, 29(3): 272-278. DOI: 10.1200/JCO.2010.29.1609. ［14］ Xie SS, Li M, Zhou CC, et al. Prophylactic cranial irradiation may impose a detrimental effect on overall survival of patients with nonsmall cell lung cancer: a systematic review and metaanalysis［J］. PLoS One, 2014, 9(7): e103431. DOI: 10.1371/journal.pone.0103431. ［15］ Li N, Zeng ZF, Wang SY, et al. Randomized phase Ⅲ trial of prophylactic cranial irradiation versus observation in patients with fully resected stage ⅢAN2 nonsmallcell lung cancer and high risk of cerebral metastases after adjuvant chemotherapy［J］. Ann Oncol, 2015, 26(3): 504-509. DOI: 10.1093/annonc/mdu567. ［16］ Niwińska A. Brain metastases as site of first and isolated recurrence of breast cancer: the role of systemic therapy after local treatment［J］. Clin Exp Metastasis, 2016, 33(7): 677-685. DOI: 10.1007/s1058501698021. ［17］ Tham YL, Sexton K, Kramer R, et al. Primary breast cancer phenotypes associated with propensity for central nervous system metastases［J］. Cancer, 2006, 107(4): 696-704. DOI: 10.1002/cncr.22041. ［18］ Graesslin O, Abdulkarim BS, Coutant C, et al. Nomogram to predict subsequent brain metastasis in patients with metastatic breast cancer［J］. J Clin Oncol, 2010, 28(12): 2032-2037. DOI: 10.1200/JCO.2009.24.6314. ［19］ HedayatizadenOmran A, Rafiei A, AlizadenNavaei R, et al. Role of HER2 in brain metastasis of breast cancer: a systematic review and metaanalysis［J］. Asian Pac J Cancer Prev, 2015, 16(4): 1431-1434. ［20］ Canney P, Murray E, DixonHughes J, et al. A prospective randomised phase Ⅲ clinical trial testing the role of prophylactic cranial radiotherapy in patients treated with trastuzumab for metastatic breast canceranglo celtic Ⅶ［J］. Clin Oncol (R Coll Radiol), 2015, 27 (8): 460-464. DOI: 10.1016/j.clon.2015.04.033.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou.Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer[J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Wang Ying, Liu Nan, Guo Bing.Advances of antibody-drug conjugate in the therapy of metastatic breast cancer[J]. Journal of International Oncology, 2024, 51(6): 364-369.
[3]	Sa Qiang, Xu Hangcheng, Wang Jiayu.Advances in immunotherapy for breast cancer[J]. Journal of International Oncology, 2024, 51(4): 227-234.
[4]	Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong.Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer[J]. Journal of International Oncology, 2024, 51(4): 235-238.
[5]	Chen Boguang, Wang Sugui, Zhang Yongjie.Role of serum cholinesterase and inflammatory markers in the prognosis of stage ⅠA -ⅢA breast cancer[J]. Journal of International Oncology, 2024, 51(2): 73-82.
[6]	He Jiahui, Hu Qinyong.Comparative analysis of lung cancer incidence and mortality trends and risk factors in China and the United States based on GBD data[J]. Journal of International Oncology, 2024, 51(1): 29-36.
[7]	Gu Huayan, Zhu Teng, Guo Guilong.Breast microbiota and breast cancer： present and future[J]. Journal of International Oncology, 2024, 51(1): 55-58.
[8]	Wang Jing, Xu Wenting.Value of NLR， CEA combined with coagulation indicators in the differential diagnosis of benign and malignant breast nodules with a diameter ≤ 1.0 cm[J]. Journal of International Oncology, 2023, 50(9): 520-526.
[9]	Feng Chengtian, Huang Furong, Cao Shiyu, Wang Jianyu, Nanding Abiyasi, Jiang Yongdong, Zhu Juanying.Relationships between HER2 protein expression and imaging features in HER2 positive breast cancer patients[J]. Journal of International Oncology, 2023, 50(9): 527-531.
[10]	Feng Dongxu, Wu Wei, Gao Pingfa, Wang Jun, Shi Lijuan, Chen Dawei, Li Wenbing, Zhang Meifeng.Effects of miR-451 on glycolysis and apoptosis of breast cancer cells by regulating Rho/ROCK1 pathway[J]. Journal of International Oncology, 2023, 50(8): 449-456.
[11]	Pan Shulan, Liu Chang, He Ping.Effect of fritinib on angiogenesis, tumor growth and IRE1-ASK1-JNK pathway in triple negative breast cancer[J]. Journal of International Oncology, 2023, 50(8): 457-462.
[12]	Wang Wende, Zeng De.Research progress on the mechanism of endocrine therapy resistance for breast cancer[J]. Journal of International Oncology, 2023, 50(6): 352-356.
[13]	Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai.Research progress on the application of combining radiotherapy and systemic therapy in breast cancer[J]. Journal of International Oncology, 2023, 50(6): 362-367.
[14]	Zhu Jun, Huang Meijin, Li Yuan, Liu Zegang, Xun Xin, Chen Hong.Research progress on targeted therapy of breast cancer with low expression of HER2[J]. Journal of International Oncology, 2023, 50(4): 236-240.
[15]	Zhou Ting, Xu Shaohua, Mei Lin.Efficacy and safety of bevacizumab combined with capecitabine in the treatment of advanced breast cancer[J]. Journal of International Oncology, 2023, 50(3): 144-149.

Clinical consensus and progress of prophylactic cranial irradiation

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles15

Recommended Articles

Metrics

Comments